Table 4.

Hb parameters (anemia and variability) associated with mortality in multivariate analysis on all patients except for those who commenced ESA therapy during the baseline period (n = 4966)a

VariableHR95% CIP
Model with regression-based Hb parameters
    age (per 10 yr)1.551.47 to 1.64<0.001
    male1.211.07 to 1.360.002
    GFR (per 5 ml/min)0.880.85 to 0.91<0.001
    dialysis initiation1.761.52 to 2.05<0.001
    absolute Hb (intercept; g/L)0.990.98 to 0.99<0.001
    Hb trend (slope; g/L per mo)0.950.93 to 0.97<0.001
    residual SD (g/L)1.031.02 to 1.04<0.001
Model with regression-based Hb parameters and six-group classification of Hb parameters
    age (per 10 yr)1.551.47 to 1.64<0.001
    male1.201.07 to 1.360.002
    GFR (per 5 ml/min)0.870.84 to 0.90<0.001
    dialysis initiation1.801.54 to 2.08<0.001
    group III (Hb 110 to 130 g/L; reference)1.00
    group I (Hb >130 g/L)1.0010.79 to 1.270.99
    group II (Hb >130 and 110 to 130 g/L)1.201.002 to 1.450.048
    group IV (Hb 110 to 130 and <110 g/L)1.621.36 to 1.94<0.001
    group V (Hb <110 g/L)1.851.47 to 2.32<0.001
    group VI (Hb >130 and 110 to 130 and <110 g/L)1.571.24 to 1.98<0.001
  • a ESA use during baseline period was not statistically significantly associated with mortality: Epoetins versus no ESA (HR 1.11; 95% CI 0.97 to 1.27); darbepoetin versus no ESA (HR 1.08; 95% CI 0.91 to 1.28); overall χ2 = 2.39, P = 0.30.